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Electrochemiluminescence Immunoassay for Cyclosporine
Michael Vogeser, Dr. med.,* Maria Shipkova, Dr. med.,† Raül Rigo-Bonnin, PhD,‡
Pierre Wallemacq, PhD,§ Matthias Orth, Dr. med.,¶ Monika Widmann, ChTech,k
and Alain G. Verstraete, Dr. med., PhD**
Background: Cyclosporine A (CsA) is used as a posttransplanta-
tion immunosuppressant drug, and careful monitoring of CsA
concentration in whole blood is essential. A new automated
electrochemiluminescence immunoassay (ECLIA) for CsA measure-
ment has been assessed in a multicenter evaluation.
Methods: Residual EDTA whole blood samples from patients
undergoing CsA therapy after organ transplant were used in assay
evaluation at 5 clinical laboratories in Europe. Experiments included
imprecision according to CLSI EP5-A2 (within-run and intermedi-
ate), lower limit of quantiﬁcation, linearity according to CLSI EP6-
A, and recovery of commercial external quality control samples. In
addition, comparisons to liquid chromatography-tandem mass spec-
trometry methods in routine use at each investigational site and to
commercial chemiluminescent microparticle immunoassay and
antibody-conjugated magnetic immunoassay methods were
performed.
Results: Imprecision testing gave coefﬁcients of variation of less
than 9% in the 30–2000 mcg/L range for both within-run and inter-
mediate imprecision. Lower limit of quantiﬁcation of 6.8 mcg/L at one
investigational site and 1.8 mcg/L at a second site at 20% coefﬁcient
of variation were observed. Linearity was measured over the concen-
tration range 0–2000 mcg/L, yielding a deviation of less than 612%.
External quality control sample recovery by ECLIA was 93%–114%
of LC-MS/MS sample recovery. Deming regression analysis of
ECLIA method comparison to combined LC-MS/MS results yielded
a slope of 1.04 [95% conﬁdence interval (CI), 1.03–1.06] and intercept
of 2.8 mcg/L (95% CI, 1.5–4.1 mcg/L). Comparison to chemilumi-
nescent microparticle immunoassay yielded a slope of 0.87 (95% CI,
0.85–0.89) and intercept of 1.4 mcg/L (95% CI, 20.89 to 3.7 mcg/L);
comparison to antibody-conjugated magnetic immunoassay yielded
a slope of 0.96 (95% CI, 0.93–0.98) and intercept of 24.2 mcg/L
(95% CI, 27.1 to 21.2 mcg/L).
Conclusions: The data from this multicenter evaluation indicate
that the new ECLIA-based cyclosporine assay is ﬁt for its purpose,
the therapeutic monitoring of CsA.
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INTRODUCTION
Cyclosporine A (Ciclosporin, Cyclosporin, CsA) was
introduced in the early 1980’s to transplantation medicine as
the ﬁrst calcineurin inhibitor. Replacing azathioprine, the
compound became the mainstay of long-term immunosup-
pressive therapy during the following years. It was soon
recognized that due to variable enteral absorption and exten-
sive metabolism (also modulated by a number of xenobiotic
compounds), therapeutic drug monitoring is indispensable
for immunosuppressive therapy with CsA. Consequently,
a number of immunoassays and chromatographic analytical
methods for monitoring CsA have been introduced over the
years.1–4
Beginning in 2000, a second calcineurin inhibitor,
tacrolimus, became more and more widely used. Since then,
tacrolimus has been replacing CsA as the ﬁrst-line immuno-
suppressant in most institutions. The results of the Symphony
study, published in 2007, have encouraged this trend.5 How-
ever, CsA is still a key drug in transplantation medicine. In
a substantial number of stable long-term transplantation pa-
tients, CsA-based regimens are continued today. The decision
to change a patient’s therapy from tacrolimus to CsA may be
made in situations where speciﬁc side effects of tacrolimus
occur.6 Furthermore, there is debate about a higher incidence
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of diabetes being observed under tacrolimus therapy as com-
pared with CsA.7–11 In addition, CsA is the only immunosup-
pressant approved for the treatment of graft-versus-host
disease after bone marrow transplantation. From a global per-
spective, the lower therapy costs of CsA as compared with
tacrolimus are also relevant.
At present, the global share of CsA in transplantation
medicine is about 20%. In several of the laboratories involved
in this multicenter evaluation (MCE), 15%–20% of requests
for immunosuppressant monitoring are presently for CsA
(15% in Munich, 19% in Ghent, and 15%–20% in Brussels).
Therefore, the need remains for a robust and time-efﬁcient
CsA assay to fulﬁll the therapeutic monitoring needs of the
clinical routine laboratory.
External Quality Assessment Schemes provide insight
into performance and prevalence of diagnostic assays in
participating laboratories. Analytical Services International
administers the Ciclosporin International Proﬁciency Testing
Scheme (IPTS). IPTS is available for several immunosup-
pressive drugs and can include samples that are spiked to
a known concentration and pooled patient samples.12,13 Quan-
tiﬁcation of CsA in blood using LC-MS/MS has become more
common in clinical laboratories in recent years; however, in
the January 2014 (Cic358) report from the Ciclosporin IPTS,
almost 65% of the results reported are from measurements
made with immunoassays. The chemiluminescent micropar-
ticle immunoassay (CMIA) and the antibody-conjugated
magnetic immunoassay (ACMIA) account for approximately
40% of the immunoassay results in the January 2014 Ciclo-
sporin IPTS report. These data from the world’s largest CsA
proﬁciency testing scheme can be considered as representa-
tive of the global demand for immunosuppressant assays out-
side of the United States. In the United States, the assay
distribution is somewhat different. According to the
College of American Pathologists external Proﬁciency
Testing program report for CsA from 2008, approximately
85% of program participants used immunoassays and
approximately 75% of participants used the CMIA immu-
noassay. This suggests that implementation of LC-MS/MS
methods is still a major challenge for the clinical routine
laboratory. However, the number of participating laborato-
ries in the proﬁciency testing programs does not necessar-
ily reﬂect the number of patients monitored by different
methods. Indeed, laboratories that infrequently perform
CsA tests may be less likely to establish and maintain an
LC-MS/MS method.
Automated immunoassays for immunosuppressive drug
monitoring are clearly important for the modern clinical
routine laboratory. A new automated electrochemilumines-
cence immunoassay (ECLIA) for the quantiﬁcation of CsA in
whole blood has been developed to be implemented on an
existing commercial analyzer. Thorough evaluation of this
test is of importance for the transplantation medicine
community. The aim of this MCE involving 5 clinical
laboratories in Europe was to examine reproducibility, lower
limit of quantiﬁcation (LLOQ), linearity, and agreement of
results between the new assay and other methods that are
currently in use.
MATERIALS AND METHODS
An MCE of the ECLIA assay was conducted from
October 2012 to April 2013 at 5 European investigational
sites in Germany (Klinikum-Stuttgart, Stuttgart and Hospital
of the University of Munich, Munich), Belgium (University
Hospital St. Luc, Brussels and Ghent University Hospital,
Department of Laboratory Medicine, Ghent), and Spain
(Laboratori Clinic Department, Hospital Universitari de
Bellvitge, Barcelona). Waivers were obtained from the Ethics
Committees of the respective institutions, when remnant
samples from the institution were used, before clinical study
work began. Blood samples evaluated at the Ghent site were
shipped frozen on dry ice from other investigational sites. In
addition, all investigational sites conducted the study in
accordance with the Declaration of Helsinki (rev. Tokyo,
Venice and Hong Kong) and following ICH Good Clinical
Practice guidelines.
Immunoassays
The ECLIA (Elecsys Cyclosporine; Roche Diagnostics
GmbH, Mannheim, Germany) assay for use on the cobas e
analyzer (Roche Diagnostics) uses the principle of electro-
chemiluminescence for measurement14 (Fig. 1). The develop-
ment of ECLIA is based on the use of a ruthenium complex
and tripropylamine. The materials to be measured [calibrators,
quality control (QC) material, or patients’ whole blood sam-
ples] are equilibrated to room temperature (18–258C) and
mixed without vortexing directly before use to resuspend any
FIGURE 1. Schematic representation of the ECLIA measuring principle. Pretreated samples are combined with biotinylated an-
alyte-specific antibodies and labeled analyte derivatives and recovered with streptavidin microparticles.15 Detection is by elec-
trochemiluminescence (see Materials and Methods).
Ther Drug Monit ! Volume 36, Number 5, October 2014 Cyclosporine Multicenter Analytical Evaluation
! 2014 Lippincott Williams & Wilkins 641
sedimented erythrocytes. Three hundred microliters of the
material to be measured is combined with 300 mL of Elecsys
ImmunoSuppressive Drug (ISD) Sample Pretreatment Reagent
(Roche Diagnostics), a methanol-based solution containing
zinc sulfate, in a microcentrifuge tube. The tube is capped
and vortexed for at least 10 seconds. The samples are then
centrifuged for 4 minutes in a microcentrifuge at $10,000g.
The supernatant is decanted into a Hitachi sample cup and
capped until loading onto the system. Once in the analyzer,
in a ﬁrst 9-minute incubation step, 20 mL of pretreated sample
is incubated with a CsA-speciﬁc biotinylated antibody and
a ruthenium complex-labeled CsA derivative. Formation of
the respective immune complex depends on the CsA concen-
tration in the sample. The antibody binding site is occupied
partially with CsA from the sample and partially with rutheny-
lated hapten. In the next step, streptavidin-coated magnetic
microparticles are added. During the second 9-minute incuba-
tion, the entire complex becomes bound to the solid phase
through interaction of biotin and streptavidin. The reaction
mixture is aspirated into the measuring cell where the micro-
particles are magnetically captured onto the surface of the elec-
trode. Unbound substances are removed by a washing step,
and application of voltage to the electrode induces chemilumi-
nescent emission, which is measured by a photomultiplier.15
According to the competitive assay design, an inverse propor-
tional calibration curve is obtained.
Manufacturer reference standardization for the ECLIA
assay was carried out using CsA reference material (Novartis,
Switzerland). CsA reference material was analyzed according to
testing monograph DS 3142056_R_02, which speciﬁes identical
requirements as deﬁned for CsA USP material. CsA with its
deﬁned analyte content is dissolved in a deﬁned quantity of
human whole blood. This stock solution is used to manufacture
a set of reference calibrators by spiking human whole blood. The
CsA concentration of the working calibrators and of a panel of
human samples is determined using this calibration curve. The
CsA concentration values for the working calibrators obtained in
this manner represent the end of the reference standardization
and make it possible to calibrate the ECLIA assay and to
establish the particular typical Rodbard curve parameters.
Finally, in an additional value assignment, the CsA concen-
trations for the product 2-point calibrators are established. For
each product kit used at the investigational sites, the ECLIA
assay was calibrated using the Calset Elecsys Cyclosporine
(Roche Diagnostics) with 2 concentrations (typical values are 35
and 1540 mg/L). Calibrators were reconstituted according to the
manufacturer’s instructions and stored in 300 mL aliquots at
2–88C or below2158C. Calibrators were prepared for measure-
ment as described above and used for calibration within 30 mi-
nutes of preparation. Calibration was performed once per reagent
lot and as required for maintaining QC values within speciﬁed
limits (instrument speciﬁcations). The lot calibration stability
period is 28 days.
Sample measurement using CMIA (ARCHITECT
CYCLOSPORINE; Abbott Laboratories, IL) on the Abbott
Architect platform and ACMIA [Dimension Cyclosporine
(CSA), Siemens Healthcare Diagnostics, Inc., IL] on the
Siemens Dimension platform were performed according to
the manufacturers’ instructions and according to site-speciﬁc
standard operating procedures. Measurements using CMIA at
the site in Stuttgart were performed at the Marienhospital,
Stuttgart. Calibration of the CMIA and ACMIA assays on
their respective platforms were also performed according to
the manufacturer’s instructions.
The QC material, PreciControl ISD (PC ISD, Roche
Diagnostics), is available at 3 concentrations. Value assignment
for the PC ISD material is performed in an initial measurement
of a newly produced accuracy control on the cobas e 601
system by the manufacturer. The analyte content determined in
this manner is the “ﬁrst-assigned value.” This value is reported
on the value sheet for the dedicated accuracy control lot. There-
after, for the accuracy control lots that are shipped to individual
sites for use, the accuracy control is measured on every instru-
ment platform and in the current reagent standardization to
determine the platform-speciﬁc target value. The QC samples
were prepared and stored with the same method as the
calibrators. Once prepared, QC samples were measured within
30 minutes. Each instrument run was validated by measuring
the QC material and comparing control results to speciﬁed
ranges before patient sample material was measured.
In addition, each laboratory in this evaluation has
a routine internal QC program. The laboratory in Klinikum-
Stuttgart also used the QC material ClinCheck Control for
immunosuppressants (RECIPE, levels 1, 2, and 3) and More
Diagnostics Tac/CsA controls (levels 1, 2, and 3) for
Dimension. For the proﬁciency testing samples in Stuttgart
at Marienhospital, imprecision and inaccuracy of CMIA were
evaluated with Bio-Rad Lyphochek Whole Blood Immuno-
suppressant Control (levels 1, 2, and 3). The laboratory in
Munich used the Chromsystems MassCheck controls (levels
1, 2, 3, and 4). The laboratory in Barcelona used 3-level
controls containing CsA in blood lysate (ClinChek Whole
Blood Control for Immunosuppressants, lyophilized, levels 1,
2, and 3; RECIPE). The laboratory in Ghent used Chromsys-
tems MassCheck Immunosuppressants Whole Blood control,
levels 1 and 3, for LC-MS/MS; Bio-Rad Abbott IS-MCC
controls for the Architect; and More Diagnostics Tac/CsA
controls for Dimension.
During the 7-month evaluation period, adverse event
reports for the CMIA assay were posted on the FDA website
indicating arbitrary values for sample recovery related to
certain reagent lots. The sites in Ghent and Brussels were
affected by the sample recovery issue. The site in Ghent was
able to continue experiments with a different CMIA lot that
was not affected. Brussels had access only to the affected lots;
therefore, the method comparison experiments in Brussels
were discontinued.
LC-MS/MS Measurements
Each investigational site performed tandem mass
spectrometry measurements according to protocols developed
and routinely used at the site. Table 1 outlines the LC-MS/MS
method details used by each laboratory.
Sample Sources and Handling
EDTA whole blood samples from patients who had
received an organ transplant and were under CsA therapy
were collected at the respective sites (except Ghent) for
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the imprecision, LLOQ, linearity, and method comparison
experiments. Not all transplant types were available at all
investigational sites; therefore, additional residual samples
from all transplant cohorts (N = 70 per cohort) were supplied
by Roche Diagnostics to the sites in Stuttgart, Barcelona,
Brussels, and Ghent. These additional samples were col-
lected at the Institute for Clinical Chemistry, Medical Uni-
versity of Hannover under the same Institutional Review
Board/Ethics Committees and Good Clinical Practice
guidelines as outlined above. Commercial proﬁciency test-
ing samples were purchased from Analytical Services
International Ltd (London, United Kingdom). Additional
patient samples with CsA at high concentration were pur-
chased from a commercial laboratory (Cerba Specimen
Services, France). The transplant cohorts of these samples
were not identiﬁable and are indicated as “unknown” in the
results. The number of samples measured for each experi-
ment is described in the Results section.
Samples were prepared for immunoassay measurement
as described above. Samples not collected at site were
shipped frozen on dry ice in a thermal container and inspected
upon arrival to ensure sample integrity, and stored at 2158C
TABLE 1. Details of LC-MS/MS Methods Used by Investigational Sites in the MCE
Laboratory
Instrument (HPLC/
MS)
Working
Range, mcg/L Sample Preparation Internal Standard Calibration (Daily)
Chromatographic
Separation (Analytical
Column; Mobile Phase;
Column Temperature;
Injection Volume; Run
Time)
Barcelona Waters Acquity UPLC/
Waters TQD
15–1963 Protein precipitation with
ZnSO4
[D12]-Cyclosporine
A
Seven-level calibrators
(ClinCal whole blood
calibrator set,
lyophil., level 0–6;
RECIPE)
MassTrak TDM C18 2.1 ·
10 mm (Waters); A:
0.1% (vol/vol) formic
acid and 2 mmol/L
ammonium acetate in
water, B: 0.1% (vol/
vol) formic acid and
2 mmol/L ammonium
acetate in methanol;
558C; 20 mL in 50 mL
loop; 2.5 min run time
Brussels Agilent 1290 Inﬁnity/
Agilent 6460 series
20–1250 Protein precipitation with
ZnSO4
[D12]-Cyclosporine
A
“Home made” with
RECIPE calibrators
Zorbax Eclipse XDB C18
4.6 · 50 mm (Agilent);
A: 60% methanol (aq),
B: 2 mmol/L
ammonium acetate,
0.5% formic acid (aq),
5% acetonitrile with
95% methanol; 608C;
40 mL; 3 min run time
Ghent Waters Acquity UPLC/
Waters TQD
4.76–1250 Protein precipitation with
ZnSO4
[D12]-Cyclosporine
A
Chromsystems
MassCheck
Immunosuppressants
whole blood
calibrator (one point,
in duplicate)
(Chromsystems)
MassTrak TDM C18 2.1 ·
10 mm (Waters); A:
2 mmol/L ammonium
acetate and 0.1% formic
acid in water; B: 2
mmol/L ammonium
acetate and 0.1% formic
acid in methanol; 508C;
10 mL; 1.8 min run time
Munich Waters Alliance 2795/
Waters Quattro
Ultima Pt
43–913 Protein precipitation with
ZnSO4 followed by on-
line solid phase extraction
4-fold deuterated
cyclosporine A
6-point; Chromsystems
Calibrator Set
(Chromsystems)
Sunﬁre C18 5 mm, 2.1 ·
100 mm (Waters);
90% methanol/10%
2 mmol/L ammonium
acetate; 508C; 10 mL;
4.5 min run time
Stuttgart16,17 Waters Alliance 2695/
Waters Quattro micro
API
10–1800 Protein precipitation with
ZnSO4
Cyclosporine D 6-point; Chromsystems
Calibrator Set
(Chromsystems)
MZ Aqua Perfect C18
5 mm, 150 · 3.0 mm
(MZ-Analysentechnik);
A: 2 mmol/L
ammonium acetate,
0.1% formic acid
(aqueous), B: 2 mmol/L
ammonium acetate,
0.1% formic acid in
methanol; 658C; 30 mL;
5.5 min run time
Ther Drug Monit ! Volume 36, Number 5, October 2014 Cyclosporine Multicenter Analytical Evaluation
! 2014 Lippincott Williams & Wilkins 643
or below until testing occurred. Samples collected at site were
stored at room temperature (18–258C) if tested within 8 hours
of collection or at 2–88C if tested within 1 week. If longer
storage was necessary, samples were stored below 2158C.
Liquid whole blood aliquots used for the method comparison
were measured within 24 hours using all methods. Between
method comparison measurements, the aliquots were stored at
2 to 88C. Aliquoted samples were treated in a deﬁned way and
did not undergo more than 1 freeze/thaw cycle. Frozen sam-
ples were thawed and mixed thoroughly before use. Whole
blood samples were never centrifuged.
Imprecision and Inaccuracy
Assay imprecision was tested in Stuttgart and Ghent
according to protocol CLSI EP5-A218 on a cobas e 411 sys-
tem and a cobas e 602 system. Imprecision was determined
using 84 aliquots each of the PreciControl ISD material at 3
concentrations and of 5 pooled EDTA whole blood samples
with deﬁned concentration ranges from 30 to 2000 mcg/L
(Table 2). Controls and samples were frozen in 300 mL ali-
quots and stored below 2158C. For each measuring day, 1
aliquot of each sample and control was thawed. Before the
ﬁrst run on day 1, instrument calibration was performed. One
run was performed per day over 21 days, and samples were
randomized. Four replicates per sample were measured.
Mean, median, minimum, maximum, within-run, intermedi-
ate imprecision [SD and coefﬁcient of variation (CV)%], and
inaccuracy were calculated in the Windows-based Computer
Aided Evaluation (WinCAEv) program (Roche Diagnos-
tics19). Acceptance criteria for intermediate imprecision were
based on Oellerich et al20: at a concentration of 50 mcg/L, CV
#10%; at a concentration of 300 mcg/L, CV #5%. Inaccur-
acy was calculated using the measurement results from the
PreciControl ISD material.
Lower Limit of Quantification
LLOQ was assessed in Stuttgart and in Ghent on a cobas e
411 system and a cobas e 602 instrument.21 Pooled EDTA whole
blood samples with target concentrations at approximately 10,
20, 30, 40, and 50 mcg/L were used and 14 aliquots with a vol-
ume greater than 300 mL were prepared. Samples were measured
in 1 run each day for 10 days in total with a single measurement
per aliquot. Mean, median, minimum and maximum values, SD,
and CV were calculated in WinCAEv.
Linearity
Linearity testing was performed in Stuttgart and Ghent
on a cobas e 411 system and a cobas e 602 system according to
the polynomial method described in CLSI EP6-A22 that eval-
uates nonlinearity. The method consists of 2 steps. The ﬁrst
step examines whether a nonlinear polynomial equation pro-
vides a superior ﬁt to the data than a linear equation. The
second step assesses whether the differences between the
best-ﬁtting nonlinear and linear equation are less than the spec-
iﬁed bias for ECLIA. As the medically relevant range for
trough sampling covers mainly the lower part of the measuring
range, weighting functions (quadratic and inverse concentra-
tion) were applied to test results of the dilution series. The
dilution series were prepared as follows: A 24 mL pool of
whole blood sample with low CsA concentration was prepared
for the experiment. A 12-mL aliquot of this pool was spiked
with CsA to a concentration greater than 2100 mcg/L. The
TABLE 2. Imprecision and Bias of the ECLIA Assay
Target
Concentration,
mcg/L
Within-Run
(CV), %
Intermediate
(CV), %
Mean,
mcg/L
Bias (Mean),
%
Stuttgart cobas e 411
PreciControl ISD level 1 66.0 4.2 6.8 72 10
PreciControl ISD level 2 324 3.4 4.7 345 7
PreciControl ISD level 3 1202 3.2 4.6 1329 11
HSP 1: 30–90 mcg/L 3.8 8.5 53
HSP 2: 90–300 mcg/L 2.8 5.0 143
HSP 3: 300–600 mcg/L 3.5 4.7 468
HSP 4: 700–1400 mcg/L 3.1 5.3 1154
HSP 5: 1500–2000 mcg/L 4.2 5.8 1880
Ghent cobas e 602
PreciControl ISD level 1 72.7 4.6 6.1 76 4
PreciControl ISD level 2 336 3.3 4.9 334 0
PreciControl ISD level 3 1282 3.1 4.7 1251 22
HSP 1: 30–90 mcg/L 4.5 6.6 63
HSP 2: 90–300 mcg/L 3.7 5.0 146
HSP 3: 300–600 mcg/L 2.6 4.2 378
HSP 4: 700–1400 mcg/L 3.7 5.1 1026
HSP 5: 1500–2000 mcg/L 3.0 5.4 1769
Results from measurements in Stuttgart and Ghent are shown. Within-Run and Intermediate CVs are expressed as the one-sided 95% conﬁdence interval (upper conﬁdence limit).
Approximate conﬁdence limits for the coefﬁcient of variation are calculated by normalization of the standard deviation to the respective mean.
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high concentration sample pool was then diluted with the low
concentration sample pool to create a dilution series of 15
steps. In addition, a patient sample high concentration pool
was used to create a dilution series with a low concentration
pool. Three aliquots per dilution step were prepared and mea-
sured in 1 run as 3 replicates per dilution step. Linearity was
assessed using absolute deviation from the calculated dilution
concentration in Microsoft Excel (Microsoft, Redmond, WA).
The polynomial regression analysis for ﬁrst-, second-, and
third-order polynomials and the mean, median, minimum and
maximum values, SD, and CV were calculated in WinCAEv.
External Quality Control Scheme
External QC samples from the Ciclosporin IPTS (ASI
Ltd, London, United Kingdom) were measured at all investi-
gational sites. The scheme includes samples that are either
spiked to a known concentration (“spiked” samples) or pooled
samples from patients receiving CsA immunosuppressive ther-
apy (“pooled patient” samples). IPTS samples were measured
with ECLIA on 3 different cobas platforms, with LC-MS/MS,
and with CMIA and ACMIA at selected sites. In this evaluation,
both spiked and pooled patient samples were measured. Details
of sample measurement per site and assay method are outlined
in the supplemental data (see Table 1, Supplemental Digital
Content 1, http://links.lww.com/TDM/A84). All instruments
were calibrated before the experimental run. Samples were
divided into 300 mL aliquots and measured in 1 run with 3
replicates for each sample. Mean, median, and percent recov-
eries were calculated in WinCAEv.
Method Comparison
The method comparison experiment was performed at
all investigational sites between the ECLIA on cobas e 411,
cobas e 601, and cobas e 602 platforms and LC-MS/MS
instruments; between ECLIA and CMIA in Stuttgart, Ghent,
and Brussels; and between ECLIA and ACMIA in Stuttgart
and Ghent. Due to adverse event-related recovery problems
with certain CMIA assay lots, the method comparison
experiments in Brussels with this platform were discontinued.
Residual samples from patient cohorts for liver, kidney, heart,
lung, and bone marrow transplant were measured with 1
replicate per method. More than 60 samples per transplant
type were measured, with the total number of samples
measured indicated in the respective plots in the Results
section. Slope, intercept, and Pearson’s r were calculated in
WinCAEv. Discrepant results were handled as outlined
below. Comparisons were calculated using weighted Deming
regression. The intermediate imprecisions for each LC-MS/
MS method from the investigational sites were used to calcu-
late the imprecision ratio in the weighted Deming regression.
Acceptance criteria against LC-MS/MS were based on the
recommendation of Oellerich et al20 and deﬁned as a slope
of 1.00 6 0.10 and an intercept of 615 mcg/L or less.
Discrepant Results
Discrepant results were compared with the respective
result obtained with tandem mass spectrometry. All samples
showing more than 40% difference to LC-MS/MS results were
regarded as discrepant. If sufﬁcient sample volume remained,
the discrepant sample was retested in triplicate using all assays.
If insufﬁcient sample volume remained for retesting with all
assays, testing was repeated in 1 of 2 ways. Either the sample
was remeasured in triplicate using the assay(s) which showed
the most discrepant value as compared with the other assays
used at that site, or the sample was remeasured in single or
duplicate for 2 or more assays used at that site, according to the
remaining sample volume available.
RESULTS
Imprecision and Inaccuracy
Results for within-run and intermediate imprecision of
the ECLIA assay are given in Table 2. In the human sample
pools at concentrations less than 90 mcg/L, the within-run CV
was below 4.5% at both sites. At a concentration between 90
and 600 mcg/L, the CV values were 3.7% or less for both
sites. At concentrations $700 mcg/L, CVs ranged from 3.0%
to 4.2%. Intermediate imprecision results in Stuttgart were
a CV of 8.5% and in Ghent 6.6% for the sample pool with
a target concentration less than 90 mcg/L (acceptance crite-
rion #10%). Between 90 and 600 mcg/L, the CV’s for both
sites were 5.0% or less (acceptance criterion #5%). At con-
centrations $700 mcg/L, CVs ranged from 5.1% to 5.8%.
Bias as evaluated with the PreciControl ISD material (Table
2) ranged from 22% to 11%.
Lower Limit of Quantification
The LLOQ of the assay was determined as 6.8 mcg/L in
Stuttgart and 1.8 mcg/L in Ghent at 20% CV. The concen-
trations of 29.7 mcg/L in Stuttgart and 15.9 mcg/L in Ghent
could be determined with a CV of 10% (Fig. 2).
Linearity
Figure 3 shows the results from Stuttgart and Ghent for
the linearity experiment, with both the patient pool and spiked
sample pools plotted as the expected concentration against the
absolute deviation of each sample from the expected result as
calculated by the linear model. The maximum difference
FIGURE 2. Lower limit of quantification of the ECLIA assay. LLOQ
was assessed via measurement of 5 samples at low CsA concen-
tration at 2 investigational sites on 2 different cobas platforms. CsA
recovery at 10% and 20% CV are indicated for each site.
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between linear and quadratic models was 11.9%, and the max-
imum difference between linear and cubic models was 8.9%.
External Quality Control Scheme
Results from external QC (IPTS) sample measurements
obtained in this MCE are outlined in Table 3, as well as
overall results from the participating IPTS laboratories as
summarized in the program reports. The mean and SD of
the measurements from all sites per method are indicated,
and comparison of each method to the IPTS reported overall
“HPLC/MS” results (which includes both HPLC/MS and
HPLC/MS/MS methods) are reported separately for pooled
patient and spiked samples.
Comparison of the mean results with pooled patient
samples from the MCE measurements between ECLIA and
the “HPLC/MS” overall results from IPTS shows a difference
of 11%, while it is 4% and 19% for ACMIA and CMIA MCE
results and 2% and 5% for the overall ACMIA and CMIA
results. Comparison of the spiked samples on average yielded
smaller differences. Comparing ECLIA mean MCE results
with spiked samples to “HPLC/MS” overall results yields
a difference of 4%, 25%, and 12% for ECLIA, ACMIA
and CMIA results, respectively. For the overall results, the
differences are 2% for ACMIA and MCIA. The External
Quality Assessment Schemes sample recovery distributions
per instrument for each sample are also displayed using
box-and-whiskers plots (see Figure 1, Supplemental Digital
Content 1, http://links.lww.com/TDM/A84).
Method Comparison
Method comparison by weighted Deming regression
analysis and Bland–Altman graphical representation of the val-
ues obtained from each method are displayed in Figures 4A–F.
Figure 4A is the Deming regression of the LC-MS/MS meas-
urements from all sites versus ECLIA, with 1643 data points.
The slope is 1.04 [95% conﬁdence interval (CI), 1.03–1.06;
acceptance criterion: 0.9–1.1], the intercept is 2.8 mcg/L (95%
CI, 1.5–4.1 mcg/L; acceptance criterion: 615 mcg/L or less),
and the Pearson’s r is 0.98. All values are within the accep-
tance criteria outlined by Oellerich et al.20 Figure 4B shows
a Bland–Altman difference plot of the LC-MS/MS comparison
data#500 mcg/L, with the normalized difference expressed as
percentage on the y axis. The mean bias is 7.5% of the average,
with 2 SD limits of 221.1% and 36.2%. Samples from the
heart transplant cohort that had results outside of the 2 SD
limits showed a trend toward deviation greater than the upper
2 SD limit at concentrations greater than 200 mcg/L, and bone
marrow samples outside of the 2 SD limit trended toward
deviation less than the lower 2 SD limit.
Results of the comparison between ECLIA and CMIA are
shown in Figures 4C and D. As described in the Materials and
Methods, some CMIA lots had adverse event reports posted on
the FDA Web site during the course of this study with arbitrary
values affecting CsA recovery. The sites in Ghent and Brussels
also experienced an effect on analyte recovery due to these
technical issues. The site in Ghent was able to continue meas-
urements with an unaffected lot already on hand. The Deming
regression analysis in Figure 4C using 682 paired data points
yielded an equation of y = 1.40 + 0.87 · (95% CI slope, 0.85–
0.89; 95% CI intercept, 20.89 to 3.7 mcg/L), with a Pearson’s
r of 0.98. While the Pearson’s r is close to 1, the slope shows
a greater difference between ECLIA and CMIA than between
ECLIA and LC-MS/MS methods (see also Figure 2A, Supple-
mental Digital Content 1, http://links.lww.com/TDM/A84,
comparison of LC-MS/MS and CMIA). The Bland–Altman
plot (Fig. 4D) of the same data set also reﬂects this bias by
CMIA in comparison to ECLIA results for most transplant
types, with a mean bias of 212.2% and 2 SD limits of
19.8% and 244.1%. The heart samples showed a trend to be
greater than the upper 2 SD limit of 19.8%.
Comparison of ECLIA to ACMIA is displayed in
Figures 4E and F, with 679 paired data points used in
the regression analysis. The slope determined is 0.96 (95%
CI, 0.93–0.98), the intercept is 24.15 mcg/L (95% CI, 27.1
to 21.2 mcg/L), and the Pearson’s r is 0.98. These results are
comparable to the comparison of ECLIA with LC-MS/MS
FIGURE 3. Linearity assessment of the ECLIA assay in
pooled patient blood and spiked samples. Linearity
was assessed according to CLSI EP6-A using 15 dilu-
tion steps at 2 investigational sites on 2 different co-
bas platforms with a pooled patient and a spiked
sample pool. The data were fitted to a linearity
model. The absolute deviation to the model for each
dilution point is indicated on the y axis.
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but also show a bias by ACMIA in comparison to the
ECLIA results (see also Figure 2B, Supplemental Digital
Content 1, http://links.lww.com/TDM/A84). Bland–Altman
analysis (Fig. 4F) conﬁrms this observation with a mean bias
of28.8% between the 2 results over the entire measuring range,
and upper and lower 2 SD limits of 20.7% and238.3%, respec-
tively. By visual inspection, the transplant types were distributed
equally over the 2 SD limits.
These method comparison data are also displayed as
Deming regression analysis, with each site indicated by
a different symbol in the Supplemental Digital Content 1
(see Figure 3A–C, http://links.lww.com/TDM/A84). In
addition, the individual Deming regression for comparison
between ECLIA and LC-MS/MS for each transplant type is
shown in the Supplemental Digital Content 1 (see Figure
4A–E, http://links.lww.com/TDM/A84). Discrepant results
were observed for 81 samples (3%). After re-analysis, the
discrepancy was resolved in 72 cases and remained in 9
cases.
With respect to comparison of sample throughput,
ECLIA as well as CMIA and ACMIA can process approx-
imately 70 samples per hour, whereas the LC-MS/MS method
allows a throughput of roughly 10–30 tests per hour, depend-
ing on the speciﬁc method parameters and run time.
DISCUSSION
In an MCE of the new ECLIA assay conducted at 5
study sites, good assay imprecision, with linearity over a wide
measuring range and close agreement with LC-MS/MS
methods, and proﬁciency testing results were observed. The
LLOQ of the test (at an interassay coefﬁcient of variation
of ,20%) was found to be less than 10 mcg/L. This is sub-
stantially below the target range of CsA. Within the range of
the typical therapeutic window, CVs clearly below 10% were
observed. According to the linearity experiment results, the
ECLIA assay is linear in the range of 30–2000 mcg/L. The
absolute deviation from a linear ﬁt to the results increases toward
TABLE 3. External Quality Control Scheme Results From IPTS Samples (Both MCE Data and Overall External Quality Control Data
From IPTS Scheme)
IPTS Sample Number
328 329 335 337
A Spiked A Spiked B Pooled C Spiked B Spiked A Spiked B Spiked
ECLIA MCE, N 12 12 12 12 15 15 15
Mean 6 SD, mcg/L 494.0 6 25.7 26.8 6 2.8 205.5 6 6.4 367.9 6 15.4 541.7 6 14.1 55.1 6 4.9 160.9 6 6.3
LC/MS–MS MCE, N 9 9 9 9 15 15 15
Mean 6 SD, mcg/L 508.0 6 30.4 27.6 6 2.7 184.2 6 16.8 371.9 6 20.3 502.3 6 54.1 55 6 3.6 149.1 6 7.4
HPLC/MS overall, N 118 117 124 124 123 133 133
Mean 6 SD, mcg/L 487.0 6 28.5 27.4 6 4.2 186.5 6 13.4 357.8 6 26.7 506.7 6 36.9 53.8 6 4.4 154.2 6 11.8
ACMIA MCE, N 6 6 6 6 6 6 6
Mean 6 SD, mcg/L 475.7 6 12.0 22.5 6 2.5 205.1 6 22.3 386.2 6 49.5 513.2 6 13.1 48.2 6 4.5 157.0 6 8.2
ACMIA overall, N 138 78 88 88 87 89 89
Mean 6 SD, mcg/L 500.3 6 39.0 27.4 6 6.6 194.6 6 14.1 390.0 6 22.9 530.7 6 45.1 55.2 6 7.2 162.6 6 9.6
CMIA MCE, N 6 6 6 6 9 9 9
Mean 6 SD, mcg/L 479.1 6 61.1 29.6 6 4.2 209.3 6 9.1 386.0 6 20.3 567.4 6 36.5 52.4 6 11.0 155.4 6 19.6
CMIA overall, N 133 91 107 106 111 110 110
Mean 6 SD, mcg/L 517.8 6 54.4 28.1 6 4.2 194.8 6 24.4 358.5 6 47.7 527.8 6 53.7 56.2 6 8.7 153.7 6 17.6
IPTS Sample Number
338 339 340 342
A Pooled C Pooled C Spiked A Spiked
ECLIA MCE, N 15 6 15 6
Mean 6 SD, mcg/L 134.1 6 5.8 190.1 6 4.1 118.8 6 6.3 478.4 6 14.4
LC/MS–MS MCE, N 15 6 15 6
Mean 6 SD, mcg/L 117.6 6 8.9 171.1 6 8.8 116.0 6 14.4 444.3 6 28.1
HPLC/MS overall, N 132 135 134 140
Mean 6 SD, mcg/L 120.4 6 8.1 170.0 6 13.6 115.5 6 8.6 444.4 6 37.2
ACMIA MCE, N 6 6
Mean 6 SD, mcg/L 117.1 6 5.5 102.4 6 2.7
ACMIA overall, N 89 87 84 83
Mean 6 SD, mcg/L 119.4 6 9.8 176.2 6 13.3 107.4 6 10.4 453.4 6 27.1
CMIA MCE, N 9 3 9 3
Mean 6 SD, mcg/L 142.2 6 16.7 216.2 6 29.5 124.5 6 19.5 652.8 6 19.5
CMIA overall, N 105 100 109 111
Mean 6 SD, mcg/L 126.2 6 17.3 181.5 6 20.3 116.0 6 15.1 464.9 6 52.5
Values shown are the mean of a given method’s measurement results from all participating laboratories, including replicates. Results from the current MCE Study are indicated by
“MCE”. “Pooled” is pooled patient blood samples. “N” is number of samples.
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FIGURE 4. A–F, Method comparison of the ECLIA assay versus LC-MS/MS, CMIA, and ACMIA. Method comparison of the ECLIA assay
against LC-MS/MS (A, B), CMIA (C, D), and ACMIA (E, F) was performed using both weighted Deming regression and Bland–Altman
analysis. Data points from 0 to 500 mcg/L are displayed in the full-sized figure and the full range of the data points is displayed as an
inset in the graph. Regression parameters and 95% CI (calculated using the entire measuring range) are indicated within the plot. Five
transplant cohorts and commercially obtained samples of unknown transplant type are indicated with different symbols in each graph.
The dashed line in the regression plots parallel to the x axis represents the lower limit of the ECLIA assay measuring range, the unity line,
and the fitted line. Bland–Altman plots with data from 0 to 500 mcg/L are displayed using the average of the 2 methods on the x axis
and the normalized difference in percentage on the y axis. The bias and 62 SD range are indicated with dashed lines.
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the higher end of the measuring range, as expected based on the
weighting function applied to the dilution series results.
The recommendations for intermediate imprecision ac-
cording to Oellerich et al20 were met for samples,700 mcg/L.
Applying the same criterion (CV #5%) for all concentrations
$300 mcg/L, the criterion was not met for 2 samples, human
sample pools 4 and 5, in both Stuttgart and Ghent. The highest
observed CV in this range was 5.8% in Stuttgart. It must be
noted, however, that for the most widely used CsA immuno-
assay, the CMIA method, CVs ranging from 6.6% to 14.3% in
the concentration range from 343 to 464 mcg/L are reported in
a multicenter study.23 Thus, the data from the ECLIA evalua-
tion demonstrate a superior assay imprecision.
The analysis of a representative set of proﬁciency
testing samples demonstrated good agreement of ECLIA
results with the average results of overall LC-MS/MS user
laboratories who participated in the external quality scheme,
with a difference of 11% for pooled patient IPTS samples and
4% for spiked samples. It is worthwhile noting that pooled
patient samples may have the result that extremes of CsA
metabolism are averaged out, preventing a true “real-world”
picture of cross-reactivity ranges in a set of individual patient
samples. Nonetheless, the observation that ECLIA results
from IPTS pooled patient samples gives results that are
11% higher than LC-MS/MS, and 4% higher for spiked sam-
ples, suggests that the ECLIA calibrators are not biased.
These observations are in line with the comparative
measurement of more than 1600 samples using 5 different
LC-MS/MS methods in this multicenter study: close correlation
(Pearson’s r = 0.98) was found with a slope of 1.04 (95% CI,
1.03–1.06) and a negligible intercept. Assessment of the paired
results (1516 data points at#500 mcg/L) according to Bland and
Altman also demonstrated slightly higher results, with ECLIA
displaying a mean difference of +7.5% compared to LC-MS/MS.
Cross-reactivity with metabolites commonly found in whole
blood samples for the ECLIA assay was evaluated during assay
development by the manufacturer, based on guidance from CLSI
document EP7-A2. At 2000 mcg/L, cross-reactivity was 6% for
AM9, 2% for AM1 and AM4n, and not detectable for AM1c,
AM1c9, and AM19 (see Table 2, Supplemental Digital
Content 1, http://links.lww.com/TDM/A84).24 Consequently,
this small bias is most likely explained by some degree of
between-method variance in LC-MS/MS standardization rather
than the ECLIA assay calibrators, as mentioned above. However,
the standardization of the test is in full agreement with the rec-
ommendations of a consensus panel on CsA monitoring.20 In the
article from the consensus panel, a slope of #10% when com-
pared with a chromatographic method as a reference is recom-
mended to demonstrate that a method accurately measures CsA
concentration.
When compared to LC-MS/MS, the CMIA assay
had a substantially higher slope (1.28) for a set of 697
samples (see Figure 2A, Supplemental Digital Content 1,
http://links.lww.com/TDM/A84). This is surprising, as results
from an MCE of the CMIA assay reported slopes of 0.87–0.92
in comparison to LC-MS/MS.23 In addition, measurement of
the proﬁciency testing samples demonstrated good agreement
between CMIA results and LC-MS/MS methods. However, the
original CMIA measurements reﬂected in the overall
proﬁciency testing results were performed at an earlier time
point, most likely with different reagent lots than those used
in the MCE. This difference is a plausible cause for the differ-
ent slopes observed in the method comparisons.
Test handling of the ECLIA assay was found to be
convenient, although it involves a manual protein precipitation
step preceding the automated analysis. This step accounts for
additional workload compared to usual immunoassay tests;
however, protein precipitation is expected to address the issue
of heterophilic antibodies. Such anti-reagent antibodies repre-
sent a major pitfall of immunoassays, and removal of antibodies
consequently contributes to improved patient safety.25,26 Nev-
ertheless, this precipitation step requires labeling and handling
of one additional tube and must be recognized as a potential
source of gross error when compared to other fully automated
assays implemented on cobas analyzers.
The assay offers a wide measuring range up to 2000
mcg/L. This is of relevance regarding postapplication sam-
pling strategies, as done in AUC studies and mainly in the
C2-approach, with sampling 2 hours after oral administration
of CsA.27,28 Although this approach is rarely applied in the
countries represented by the investigational sites in this eval-
uation, it is an important option for the test to be applicable in
this setting without need for sample dilution.
The concept of an MCE of a new commercial reagent
tries to address as many recognized and unrecognized variables
of different instruments and sites as possible (different
instrument lots; differential pattern of other tests run on
respective instrument, throughput, environmental conditions;
skill of operators; shipment and storage of reagents, etc.) in an
industry–academic cooperation. In the particular case of CsA,
comparative measurement with different systems in use at the
different sites and heterogeneous LC-MS/MS methods were of
particular importance. Consequently, this extensive set of data
allows for a thorough appraisal of the test performance before it
is commercially available. Nevertheless, long-term stability
and lot-to-lot consistency of an immunoassay is an essential
challenge for assay manufacturers, requiring careful ongoing
assessment of the assay performance, both by the manufacturer
and by the users.
CONCLUSION
In summary, we conclude from the data of this large
MCE that the new ECLIA assay is ﬁt for its purpose, the
therapeutic drug monitoring of CsA in transplantation medicine.
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